Back to News
Market Impact: 0.55
Eli Lilly To Acquire Merida Biosciences In $2.875 Bln Deal
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Eli Lilly agreed to acquire Merida Biosciences in a deal valued at up to $2.875B, expanding its precision-therapeutics pipeline in autoimmune and allergic diseases. The transaction is likely supportive for LLY’s near-to-medium-term growth outlook given the targeted therapeutic focus, though exact deal timing and financial impact are not detailed here.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LLY0.60
More News
- Here's our monthly update on our 32 stocks, including 2 more names to buy
- Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More